Logo do repositório
 
Publicação

Role of microRNAs in the regulation of cardiovascular diseases : focus on remodelling

dc.contributor.authorAlmeida, Ana G.
dc.contributor.authorPinto, Fausto J.
dc.contributor.authorEnguita, Francisco J.
dc.date.accessioned2023-04-19T13:33:33Z
dc.date.available2023-04-19T13:33:33Z
dc.date.issued2019
dc.description.abstractMicroRNAs (miRNAs) are a large class of noncoding RNAs that regulate the expression of protein-coding genes at the post-transcriptional level . They are recognized as regulators of biological processes underlying cardiovascular disorders including hypertrophy, ischemic heart disease, valvular disease and arrhythmias. Particularly, circulating miRNAs are promising biomarkers of cardiovascular pathology (1). MiRNAs are small, noncoding, RNA molecules with approximately 22 nucleotides in length, which act as post-transcriptional regulators of gene expression. Individual miRNAs have been demonstrated to negatively regulate the expression of multiple gene transcripts by the cleavage or suppression of translation of a target mRNA. Conversely, the expression of individual genes can be regulated by multiple miRNAs. Since their experimental description in 1993 (2), a large number of miRNAs known by their gene-regulatory roles in different biological processes, have been catalogued. In fact, miRNAs are known to regulate approximately one third of all coding gene transcripts in mammals, showing their importance as key process modulators (3). Regarding cardiovascular diseases, miRNAs have been identified as key regulators of complex biological processes linked to several conditions as presented above, including left ventricular remodelling, atherosclerosis and myocardial infarction, heart failure, hypertension and arrhythmias (1). miRNAs are expressed in the cardiovascular system, but their role in cardiovascular diseases has not yet been entirely clarified. Moreover, since the discovery that miRNAs are present in the circulation, they have been investigated as novel biomarker as presented bellow. Only 3% of the human genome codes for proteins. Nevertheless, while noncoding RNAs will not act for coding into proteins they modulate all genomic functions. These noncoding RNAs include short miRNAs with approximately 22 nucleotides) and longer, with >200 nucleotides, long noncoding RNAs (lncRNAs) with important biological functions (4) since they are now clearly recognised to play key roles in gene regulation and may simultaneously represent diagnostic and prognostic biomarkers in cardiovascular diseases. (5,6) there are in excess of 2000 human miRNAs (catalogued in mirBase (http://www.mirbase.org) (7). Of note, the key feature of the mechanism of action of miRNAs is that a single miRNA can regulate the expression of several genes, depending on the specificity of the target sequence. On the other side, individual genes can be regulated by different miRNAs particularly if they involve complementary sequences for more than one miRNA. These factors lead to a highly complex regulatory mechanism, often difficult to understand. (8,9). In the healthy adult heart, data from a large sequencing project and other sequential studies, has identified a number of miRNAs that are highly expressed in healthy cardiac tissue and thus expected to play a key role in both normal cardiac function and disease. (10,11) These include miR-1, miR-16, miR-27b, miR-30d, miR-126, miR-133, miR-143, miR-208 and the let-7 family. However, many others have been identified and are now under study. The concept of miRNA-based therapeutics has been emerging and under development, with synthetic antagonists of miRNAs (antagomiRs or antimirs) and very promising in animal models but awaiting new advances in phase II human trials, still in its infancy (12,13). miRNAs clearly intervene in physiological and pathological processes in the cardiovascular diseases. We will review miRNA biology and its role on LV remodeling in myocardial infarction, heart failure, hypertension and aortic stenosis as additionally a note will be provided on the potential of miRNAs for therapeutics.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.urihttp://hdl.handle.net/10451/57191
dc.language.isoengpt_PT
dc.peerreviewednopt_PT
dc.publisherFaculdade de Medicina da Universidade de Lisboapt_PT
dc.subjectMicroRNAspt_PT
dc.subjectTerapêuticapt_PT
dc.subjectInfarto do miocárdiopt_PT
dc.subjectInsuficiência cardíacapt_PT
dc.subjectHipertensãopt_PT
dc.subjectEstenose da valvula aórticapt_PT
dc.subjectDoenças cardiovascularespt_PT
dc.subjectAntagomirspt_PT
dc.titleRole of microRNAs in the regulation of cardiovascular diseases : focus on remodellingpt_PT
dc.typebook
dspace.entity.typePublication
person.familyNameAlmeida
person.familyNamePinto
person.familyNameEnguita
person.givenNameAna Gomes de
person.givenNameFausto J.
person.givenNameFrancisco J.
person.identifier1308889
person.identifier173306
person.identifier.ciencia-id3610-3184-3042
person.identifier.ciencia-idC311-AEDD-6DBB
person.identifier.ciencia-idB215-8D49-3218
person.identifier.orcid0000-0003-0360-4363
person.identifier.orcid0000-0002-8034-4529
person.identifier.orcid0000-0002-8072-8557
person.identifier.ridG-9363-2015
person.identifier.ridA-2347-2009
person.identifier.scopus-author-id55628683100
person.identifier.scopus-author-id7102740158
person.identifier.scopus-author-id6602119231
rcaap.rightsopenAccesspt_PT
rcaap.typebookpt_PT
relation.isAuthorOfPublication7a34cb7e-96d7-426c-ac32-346c0c0fa68c
relation.isAuthorOfPublication5f44176f-69f5-482c-83cd-ab94425a6ec3
relation.isAuthorOfPublicationa101dbd4-6bf5-4546-882e-e2596eddb6b4
relation.isAuthorOfPublication.latestForDiscovery5f44176f-69f5-482c-83cd-ab94425a6ec3

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Role_MicroRNA.pdf
Tamanho:
524.2 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição: